Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
McKesson
Mallinckrodt
Colorcon
Johnson and Johnson

Last Updated: September 25, 2022

SALONPAS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Salonpas patents expire, and when can generic versions of Salonpas launch?

Salonpas is a drug marketed by Hisamitsu Pharm Co and is included in one NDA. There are two patents protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the menthol; methyl salicylate profile page.

DrugPatentWatch® Generic Entry Outlook for Salonpas

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 3, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for SALONPAS
International Patents:20
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 1
Formulation / Manufacturing:see details
DailyMed Link:SALONPAS at DailyMed
Drug patent expirations by year for SALONPAS
DrugPatentWatch® Estimated Generic Entry Opportunity Date for SALONPAS
Generic Entry Date for SALONPAS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
PATCH;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SALONPAS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Scilex Pharmaceuticals, Inc.Phase 1

See all SALONPAS clinical trials

US Patents and Regulatory Information for SALONPAS

SALONPAS is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SALONPAS is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SALONPAS

Adhesive preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Adhesive preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hisamitsu Pharm Co SALONPAS menthol; methyl salicylate PATCH;TOPICAL 022029-001 Feb 20, 2008 OTC Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Hisamitsu Pharm Co SALONPAS menthol; methyl salicylate PATCH;TOPICAL 022029-002 Nov 5, 2012 OTC Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Hisamitsu Pharm Co SALONPAS menthol; methyl salicylate PATCH;TOPICAL 022029-001 Feb 20, 2008 OTC Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Hisamitsu Pharm Co SALONPAS menthol; methyl salicylate PATCH;TOPICAL 022029-002 Nov 5, 2012 OTC Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SALONPAS

When does loss-of-exclusivity occur for SALONPAS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 07279643
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0712396
Estimated Expiration: See Plans and Pricing

Canada

Patent: 52220
Estimated Expiration: See Plans and Pricing

China

Patent: 1442993
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 47845
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 47985
Estimated Expiration: See Plans and Pricing

Japan

Patent: 2008016077
Estimated Expiration: See Plans and Pricing

Patent: 30423
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 9142
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 08014574
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 2705
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 41649
Estimated Expiration: See Plans and Pricing

Patent: 08144958
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 4034
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1420450
Estimated Expiration: See Plans and Pricing

Patent: 090035474
Estimated Expiration: See Plans and Pricing

Spain

Patent: 55027
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 14299
Estimated Expiration: See Plans and Pricing

Patent: 0817013
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SALONPAS around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2441649 АДГЕЗИВНЫЙ ПРЕПАРАТ (ADHESIVE PRODUCT) See Plans and Pricing
Singapore 174034 ADHESIVE PREPARATION See Plans and Pricing
China 101442993 Adhesive preparation See Plans and Pricing
Taiwan 200817013 Adhesive preparation See Plans and Pricing
Canada 2652220 PREPARATION ADHESIVE (ADHESIVE PREPARATION) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2008016077 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Harvard Business School
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.